UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/656,600	09/05/2003	Meir Rosenberg	22719-44 (COD5007)	7976	
21125 NUTTER MCC	7590 07/03/2007 MCCLENNEN & FISH LLP EXAMINER KOHARSKI CHRISTORHER				
WORLD TRADE CENTER WEST			KOHARSKI, C	ARSKI, CHRISTOPHER	
	EAPORT BOULEVARD ON, MA 02210-2604 ART UNIT PAPER NUMBI		PAPER NUMBER		
,	·	3763			
			MAIL DATE	DELIVERY MODE	
•			07/03/2007	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

1			
		Application No.	Applicant(s)
		10/656,600	ROSENBERG ET AL.
Office Action Summary		Examiner	Art Unit
		Christopher D. Koharski	3763
T Period for R	he MAILING DATE of this communication eply	n appears on the cover sheet with	the correspondence address
WHICHE - Extension after SIX (- If NO peri - Failure to Any reply	TENED STATUTORY PERIOD FOR RIEVER IS LONGER, FROM THE MAILIN as of time may be available under the provisions of 37 CI (6) MONTHS from the mailing date of this communication od for reply is specified above, the maximum statutory preply within the set or extended period for reply will, by sereceived by the Office later than three months after the latent term adjustment. See 37 CFR 1.704(b).	G DATE OF THIS COMMUNICA FR 1.136(a). In no event, however, may a rep in. eriod will apply and will expire SIX (6) MONTH statute, cause the application to become ABAI	ATION. ly be timely filed HS from the mailing date of this communication. NDONED (35 U.S.C. § 133).
Status			
1)⊠ Re	esponsive to communication(s) filed on	18 April 2007	
		This action is non-final.	
· 	nce this application is in condition for all		rs, prosecution as to the merits is
,—	sed in accordance with the practice und	•	•
Disposition	of Claims		
4a) 5)□ Cla 6)⊠ Cla 7)□ Cla	aim(s) <u>11-23</u> is/are pending in the application of the above claim(s) is/are with aim(s) is/are allowed. aim(s) <u>11-13,15 and 17-23</u> is/are rejected aim(s) <u>14 and 16</u> is/are objected to. aim(s) are subject to restriction a	hdrawn from consideration.	
Application	Papers		
9)∐ The	e specification is objected to by the Exa	miner.	
10)∐ The	e drawing(s) filed on is/are: a)	accepted or b) objected to by	y the Examiner.
	plicant may not request that any objection to		
	placement drawing sheet(s) including the co e oath or declaration is objected to by the		
,	er 35 U.S.C. § 119	,	Smooth of total Tropics.
•	_	roinn miority under 25 H.C.C. S.4	110(0) (1) 07 (5)
a)[] / 1.[2.[3.[ments have been received. ments have been received in Appriority documents have been received in PCT Rule 17.2(a)).	plication No eceived in this National Stage
Attachment(s)			
	References Cited (PTO-892)		mmary (PTO-413)
3) Informati	f Draftsperson's Patent Drawing Review (PTO-94 ion Disclosure Statement(s) (PTO/SB/08) o(s)/Mail Date		/Mail Date ormal Patent Application

DETAILED ACTION

Response to Amendment

Examiner acknowledges the RCE filed 4/18/2007 in which claim 11 and 17 were amended. Currently claims 11-23 are pending for examination in this application.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 11-13, 15 and 17-22 are rejected under 35 U.S.C. 102(b) as being anticipated by Dorman (4,299,220). Dorman discloses an implantable drug infusion regulator.

Regarding 11-13, 15 and 17-22, Dorman discloses an implantable drug-delivery pump comprising (Figure 1) a pump housing (25) having a reservoir (35) adapted to retain fluid therein, a pump inlet port (38) formed in the pump housing for delivering fluid form the reservoir, a driver mechanism (37) effective to drive fluid from the reservoir to the reservoir outlet port (39), a valve (15) adapted to receive fluid from the reservoir outlet port (39), the valve including a multi-lumen member (20,21) with a flexible restrictor member (15) located in a valve housing (10) to selectively restrict the one or more lumens (20,21) (Figures 1-3), wherein the restrictor member (15) extends across the sidewalls of the valve housing (10), and wherein the valve mechanism is controlled

Art Unit: 3763

by an actuation system (near 38) which is controlled by a downstream pressure sensor (24a) which is used to measure the rates of flow through the diaphragm.

Claim Rejections - 35 USC § 103

Claim 23 is rejected under 35 U.S.C 103(a) as being unpatentable over Dorman (4,299,220) in view of Haller et al. (6,048,328). Hagiwara meets the claim limitations as described above except for a pressure/flow sensor.

However, Haller et al. teaches an implantable drug infusion device.

Regarding claim 23, Haller et al. teaches an implantable drug delivery system that includes a flow sensor located downstream in the outlet to monitor flow (Figure 1).

At the time of the invention, it would have been obvious to add the sensor of Haller et al. to the modified system of Dorman because the addition of a sensor allows for a feedback control loop to control and regulate the system. The references are analogous in the art and with the instant invention; therefore, a combination is proper. Therefore, one skilled in the art would have combined the teachings in the references in light of the disclosure of Haller et al.

Allowable Subject Matter

Claims 14 and 16 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

Response to Arguments

Applicant's arguments with respect to claims 11-23 have been considered but are most in view of the new ground(s) of rejection.

Application/Control Number: 10/656,600 Page 4

Art Unit: 3763

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Christopher D. Koharski whose telephone number is 571-272-7230. The examiner can normally be reached on 7:30am to 4:00pm EST.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Nick Lucchesi can be reached on 571-272-4977. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Date: 6

NICHOLAS D. LUCCHESI SUPERVISORY PATENT EXAMINER TECHNOLOGY CENTER 3700 Christopher D. Koharski

AU 3763